REG - Byotrol PLC - Director/PDMR Shareholding

ByotrolAnnouncement

30/01/2020 17:00

RNS Number : 4897B
Byotrol PLC
30 January 2020
 


 
 
Byotrol plc
("Byotrol", the "Company" or the "Group")
 
Director/PDMR Shareholding
 
 
Byotrol Plc (AIM:BYOT), the anti-microbial technology company, announces that on 30 January 2020, John Langlands, Non-Executive Chairman of the Company, and Nic Hellyer, Chief Financial Officer of the Company, purchased 1,000,000 and 500,000 ordinary shares of 0.25p each ("Ordinary Shares") respectively at prices between 1.79 and 1.83 pence per Ordinary Share, respectively (the "Purchases").

Following the Purchases, Mr. Langlands has an interest in 9,000,000 Ordinary Shares representing approximately 2.04 per cent. of the total voting rights of the Company and Nic Hellyer has an interest in 500,000 Ordinary Shares representing approximately 0.11 per cent. of the total voting rights of the Company.
 
 
 
Enquiries:
                                                                                                              
David Traynor - Chief Executive, Byotrol plc                                                          01925 742 000
David Paton - Investor Relations                                                                            07714 190 474
finnCap Ltd                                                                                                              020 7110 0500

(Nominated Adviser & Broker)
Geoff Nash/Teddy Whiley - Corporate Finance
Richard Chambers - Corporate Broking
 
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
 
 
Notes to Editors: 
Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.
Our patented suite of technologies delivers powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.
Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to www.byotrol.co.uk
 
 
Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):
 



1.    


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


John Langlands




2.    


Reason for the Notification




a)


Position/status


Non-Executive Chairman




b)


Initial notification/Amendment


Initial




3.    


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Byotrol Plc




b)


LEI


213800AJMTSTIPA59A34




4.    


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the Financial instrument, type of instrument


ordinary shares of 0.25p each




Identification code


GB00B0999995




b)


Nature of the transaction


Purchase of Ordinary Shares




c)


Price(s) and volume(s)


Volume - 250,000
Price - 1.7975 pence
Volume - 500,000
Price - 1.83 pence
Volume - 250,000
Price - 1.79 pence




d)


Aggregated information:


Volume - 1,000,000
Aggregated price - 1.81 pence




e)


Date of the transaction


30 January 2020




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)



 
 



1.    


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Nic Hellyer




2.    


Reason for the Notification




a)


Position/status


Chief Financial Officer




b)


Initial notification/Amendment


Initial




3.    


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Byotrol Plc




b)


LEI


213800AJMTSTIPA59A34




4.    


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the Financial instrument, type of instrument


ordinary shares of 0.25p each




Identification code


GB00B0999995




b)


Nature of the transaction


Purchase of Ordinary Shares




c)


Price(s) and volume(s)


Volume - 278,164
Price - 1.7975 pence
Volume - 221,836
Price - 1.799 pence




d)


Aggregated information:


Volume - 500,000
Aggregated Price - 1.798 pence




e)


Date of the transaction


30 January 2020




f)


Place of the transaction


London Stock Exchange, AIM Market (XLON)



 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHDZGFMVGRGGZM